These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26630918)

  • 1. Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities.
    Roth HS; Hergenrother PJ
    Curr Med Chem; 2016; 23(3):201-41. PubMed ID: 26630918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics.
    Roth HS; Botham RC; Schmid SC; Fan TM; Dirikolu L; Hergenrother PJ
    J Med Chem; 2015 May; 58(9):4046-65. PubMed ID: 25856364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3.
    Peterson QP; Hsu DC; Goode DR; Novotny CJ; Totten RK; Hergenrother PJ
    J Med Chem; 2009 Sep; 52(18):5721-31. PubMed ID: 19708658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1).
    Hsu DC; Roth HS; West DC; Botham RC; Novotny CJ; Schmid SC; Hergenrother PJ
    ACS Comb Sci; 2012 Jan; 14(1):44-50. PubMed ID: 22007686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of benzothiazole derivatives bearing the ortho-hydroxy-N-acylhydrazone moiety as potent antitumor agents.
    Ma J; Zhang G; Han X; Bao G; Wang L; Zhai X; Gong P
    Arch Pharm (Weinheim); 2014 Dec; 347(12):936-49. PubMed ID: 25230149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition.
    Peterson QP; Goode DR; West DC; Ramsey KN; Lee JJ; Hergenrother PJ
    J Mol Biol; 2009 Apr; 388(1):144-58. PubMed ID: 19281821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting procaspase-3 with WF-208, a novel PAC-1 derivative, causes selective cancer cell apoptosis.
    Wang F; Liu Y; Wang L; Yang J; Zhao Y; Wang N; Cao Q; Gong P; Wu C
    J Cell Mol Med; 2015 Aug; 19(8):1916-28. PubMed ID: 25754465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and evaluation of novel (E)-N'-(3-allyl-2-hydroxy)benzylidene-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides as antitumor agents.
    Dung DTM; Park EJ; Anh DT; Hai PT; Huy LD; Jun HW; Kwon JH; Young Ji A; Kang JS; Tung TT; Dung PTP; Han SB; Nam NH
    Arch Pharm (Weinheim); 2022 Jan; 355(1):e2100216. PubMed ID: 34674294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SM-1, a novel PAC-1 derivative, activates procaspase-3 and causes cancer cell apoptosis.
    Chen Y; Sun M; Ding J; Zhu Q
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):643-54. PubMed ID: 27488460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis and Evaluation of Novel (E)-N'-((1-(4-chlorobenzyl)-1H-indol-3-yl)methylene)-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides as Antitumor Agents.
    Dung DTM; Park EJ; Anh DT; Hai PT; Bao LQ; Ji AY; Kang JS; Tung TT; Han SB; Nam NH
    Anticancer Agents Med Chem; 2022; 22(14):2586-2598. PubMed ID: 35040418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procaspase-activating compound 1 induces a caspase-3-dependent cell death in cerebellar granule neurons.
    Aziz G; Akselsen ØW; Hansen TV; Paulsen RE
    Toxicol Appl Pharmacol; 2010 Sep; 247(3):238-42. PubMed ID: 20638399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of procaspase-3 activating compounds in the induction of cancer cell death.
    West DC; Qin Y; Peterson QP; Thomas DL; Palchaudhuri R; Morrison KC; Lucas PW; Palmer AE; Fan TM; Hergenrother PJ
    Mol Pharm; 2012 May; 9(5):1425-34. PubMed ID: 22486564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel small-molecule activator of procaspase-3 induces apoptosis in cancer cells and reduces tumor growth in human breast, liver and gallbladder cancer xenografts.
    Wang F; Wang L; Zhao Y; Li Y; Ping G; Xiao S; Chen K; Zhu W; Gong P; Yang J; Wu C
    Mol Oncol; 2014 Dec; 8(8):1640-52. PubMed ID: 25053517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs.
    Lucas PW; Schmit JM; Peterson QP; West DC; Hsu DC; Novotny CJ; Dirikolu L; Churchwell MI; Doerge DR; Garrett LD; Hergenrother PJ; Fan TM
    Invest New Drugs; 2011 Oct; 29(5):901-11. PubMed ID: 20499133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and structure-activity relationships of novel benzothiazole derivatives bearing the ortho-hydroxy N-carbamoylhydrazone moiety as potent antitumor agents.
    Ma J; Chen D; Lu K; Wang L; Han X; Zhao Y; Gong P
    Eur J Med Chem; 2014 Oct; 86():257-69. PubMed ID: 25171780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and initial in vitro biological evaluation of two new zinc-chelating compounds: comparison with TPEN and PAC-1.
    Strand OA; Aziz G; Ali SF; Paulsen RE; Hansen TV; Rongved P
    Bioorg Med Chem; 2013 Sep; 21(17):5175-81. PubMed ID: 23859779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy.
    Putt KS; Chen GW; Pearson JM; Sandhorst JS; Hoagland MS; Kwon JT; Hwang SK; Jin H; Churchwell MI; Cho MH; Doerge DR; Helferich WG; Hergenrother PJ
    Nat Chem Biol; 2006 Oct; 2(10):543-50. PubMed ID: 16936720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzylidene 2-aminoimidazolones derivatives: synthesis and in vitro evaluation of anti-tumor carcinoma activity.
    Ling Y; Wang ZQ; Xiao YA; Zhu C; Shen L; Wang XM; Hui Y; Wang XY
    Chem Pharm Bull (Tokyo); 2013; 61(10):1081-4. PubMed ID: 24088700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procaspase-3-activating compound 1 stabilizes hypoxia-inducible factor 1α and induces DNA damage by sequestering ferrous iron.
    Li F; Wei A; Bu L; Long L; Chen W; Wang C; Zhao C; Wang L
    Cell Death Dis; 2018 Oct; 9(10):1025. PubMed ID: 30287840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caspase-3: A primary target for natural and synthetic compounds for cancer therapy.
    Yadav P; Yadav R; Jain S; Vaidya A
    Chem Biol Drug Des; 2021 Jul; 98(1):144-165. PubMed ID: 33963665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.